BMS-986523, BMS-986523
CA2560001
Phase 2 small_molecule active
Quick answer
BMS-986523, BMS-986523 for Advanced Solid Tumor Malignancies is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Advanced Solid Tumor Malignancies
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active